Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Prognostic or predictive biomarkers in HER2-positive early breast cancer (EBC) may inform treatment optimization. The ADAPT HER2-positive/hormone receptor-positive phase II trial (NCT01779206) demonstrated pathological complete response (pCR) rates of ~40% following de-escalated treatment with 12 we...

Full description

Bibliographic Details
Main Authors: Nadia Harbeck, Raquel von Schumann, Ronald Ernest Kates, Michael Braun, Sherko Kuemmel, Claudia Schumacher, Jochem Potenberg, Wolfram Malter, Doris Augustin, Bahriye Aktas, Helmut Forstbauer, Joke Tio, Eva-Maria Grischke, Claudia Biehl, Cornelia Liedtke, Sanne Lysbet De Haas, Regula Deurloo, Rachel Wuerstlein, Hans Heinrich Kreipe, Oleg Gluz
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
biomarkers
breast cancer
HER2-positive
hormone receptor-positive
immune markers
Online Access:https://www.mdpi.com/2072-6694/13/19/4884

Internet

https://www.mdpi.com/2072-6694/13/19/4884

Similar Items